Physician profile
Sheila Che
NPI 1275200636
$3,462.28
in general payments reported to CMS, 2019-2025
42 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.98 · 2023: $2,550 · 2024: $373 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,033 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,033.32 |
| Education | $346.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $454.68 | 2023-2025 | Calquence, Datroway, Imfinzi |
| Gilead Sciences, INC. | $400.25 | 2023-2024 | Trodelvy |
| Incyte Corporation | $371.56 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $277.03 | 2023-2025 | |
| Eisai INC. | $176.22 | 2023 | |
| Exelixis INC. | $170.33 | 2023 | Cabometyx |
| Pfizer INC. | $149.75 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.09 | 2023 | |
| Syndax Pharmaceuticals, INC. | $120.37 | 2025 | Revuforj |
| Merck Sharp & Dohme LLC | $111.09 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Sanofi-Aventis U.S. LLC | $81.98 | 2022 | |
| Seagen INC. | $56.63 | 2023 | Padcev, Tukysa |
| Taiho Oncology, INC. | $51.96 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.40 | 2023 | Ninlaro, Iclusig |
| Sobi, INC | $50.96 | 2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $49.55 | 2023 | Elahere |
| Recordati_rare_diseases_inc. | $47.37 | 2023 | Sylvant |
| Lilly USA, LLC | $45.04 | 2023 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $42.26 | 2023 | Xtandi |
| Blueprint Medicines Corporation | $42.12 | 2023 | Ayvakit |
| Genentech USA, INC. | $41.71 | 2023 | Phesgo, Polivy |
| Janssen Biotech, INC. | $41.21 | 2023 | Darzalex, Imbruvica, Erleada |
| Karyopharm Therapeutics INC. | $36.06 | 2023 | Xpovio |
| Genmab U.S., INC. | $31.81 | 2023 | Epkinly |
| Novartis Pharmaceuticals Corporation | $31.26 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $30.48 | 2023-2024 | Opdivo |
| Puma Biotechnology, INC. | $29.71 | 2023 | |
| Novo Nordisk INC | $27.36 | 2025 | Ozempic, Rybelsus |
| Genzyme Corporation | $26.33 | 2023 | |
| Fennec Pharmaceuticals, INC. | $24.91 | 2023 | Pedmark |
| Emd Serono, INC. | $24.82 | 2023 | Bavencio |
| Stemline Therapeutics INC. | $24.81 | 2023 | Orserdu |
| Alexion Pharmaceuticals, INC. | $24.42 | 2023 | Ultomiris |
| Morphosys, US INC. | $24.20 | 2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.03 | 2023 | Gilotrif |
| Mallinckrodt Hospital Products INC. | $23.19 | 2024 | Acthar |
| Adc Therapeutics America, INC. | $23.14 | 2023 | |
| Celgene Corporation | $22.94 | 2023 | Reblozyl |
| Novocure INC. | $19.93 | 2023 | Optune |
| Agios Pharmaceuticals, INC. | $19.79 | 2023 | Pyrukynd |
| Foundation Medicine, INC. | $18.97 | 2023 | Foundationone Liquid Cdx |
| Glaxosmithkline, LLC. | $13.56 | 2023 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Che listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.